Online citations, reference lists, and bibliographies.
← Back to Search

NRF2 In Human Neoplasm: Cancer Biology And Potential Therapeutic Target.

Yang Liu, F. Lang, C. Yang
Published 2020 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Nuclear factor-erythroid 2-related factor 2 (NRF2) is a master regulator of a series of cytoprotective genes, which protects cells from stress conditions such as reactive oxygen species (ROS) and electrophiles. Besides its pivotal role in cellular physiology and stress response, several recent advances revealed that NRF2-governed pathways are extensively exploited in cancer cells, and play critical roles in granting growth advantage, supporting cancer metabolism, and promoting malignant transformation. In the present review, we focus on the regulatory mechanisms of NRF2 and its roles in cancer biology. We also discuss the value of targeting NRF2-associated pathways as a means of developing future cancer therapeutics.
This paper references
Acute and chronic effects of aflatoxin on the liver of domestic and laboratory animals: a review.
P. Newberne (1969)
10.1093/NAR/17.1.37
Two tissue-specific factors bind the erythroid promoter of the human porphobilinogen deaminase gene.
V. Mignotte (1989)
10.1073/PNAS.87.22.9000
Synergistic enhancement of globin gene expression by activator protein-1-like proteins.
P. Moi (1990)
10.1126/science.7660130
Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C
A. Kibel (1995)
10.1038/378785A0
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
D. Cross (1995)
10.1073/PNAS.93.24.13943
NRF2, a member of the NFE2 family of transcription factors, is not essential for murine erythropoiesis, growth, and development.
K. Chan (1996)
10.1006/BBRC.1997.6943
An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements.
K. Itoh (1997)
10.1074/JBC.272.1.217
Epidermal Growth Factor (EGF)-induced Generation of Hydrogen Peroxide
Y. Bae (1997)
10.1074/jbc.273.32.19929
Role of Glycogen Synthase Kinase-3 in the Phosphatidylinositol 3-Kinase/Akt Cell Survival Pathway*
M. Pap (1998)
10.1038/20459
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
P. Maxwell (1999)
10.1074/JBC.274.47.33627
Regulation of gamma-glutamylcysteine synthetase subunit gene expression by the transcription factor Nrf2.
Wild Ac (1999)
10.1101/GAD.13.1.76
Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain.
K. Itoh (1999)
10.1074/jbc.274.37.26071
Nrf2, a Cap’n’Collar Transcription Factor, Regulates Induction of the Heme Oxygenase-1 Gene*
J. Alam (1999)
10.1038/35041687
Oxidants, oxidative stress and the biology of ageing
T. Finkel (2000)
10.1038/35017054
Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein
M. Ohh (2000)
10.1126/SCIENCE.1059796
Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation
P. Jaakkola (2001)
10.1126/SCIENCE.1059817
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing
M. Ivan (2001)
10.1002/mc.1030
Hydrogen peroxide promotes transformation of rat liver non‐neoplastic epithelial cells through activation of epidermal growth factor receptor
R. Huang (2001)
10.1016/S0891-5849(01)00724-9
Reactive oxygen species, antioxidants, and the mammalian thioredoxin system.
J. Nordberg (2001)
10.1046/j.1365-2443.2001.00469.x
Two domains of Nrf2 cooperatively bind CBP, a CREB binding protein, and synergistically activate transcription
Y. Katoh (2001)
10.1073/pnas.172398899
Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants
A. Dinkova-Kostova (2002)
10.1073/pnas.112203099
Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors
J. Fahey (2002)
10.1074/JBC.M208704200
Electrophile Response Element-mediated Induction of the Cystine/Glutamate Exchange Transporter Gene Expression*
H. Sasaki (2002)
10.1128/MCB.23.22.8137-8151.2003
Distinct Cysteine Residues in Keap1 Are Required for Keap1-Dependent Ubiquitination of Nrf2 and for Stabilization of Nrf2 by Chemopreventive Agents and Oxidative Stress
Donna D. Zhang (2003)
10.1042/BJ20030754
Identification of a novel Nrf2-regulated antioxidant response element (ARE) in the mouse NAD(P)H:quinone oxidoreductase 1 gene: reassessment of the ARE consensus sequence.
P. Nioi (2003)
10.1016/S1471-4906(03)00181-9
Heme oxygenase-1: unleashing the protective properties of heme.
L. Otterbein (2003)
10.1016/S0014-4827(03)00341-0
Transcription factor Nrf2 activation by inorganic arsenic in cultured keratinocytes: involvement of hydrogen peroxide.
J. Pi (2003)
10.1101/GAD.1096603
Synoviolin/Hrd1, an E3 ubiquitin ligase, as a novel pathogenic factor for arthropathy.
T. Amano (2003)
10.1016/J.MOLMED.2004.09.003
Nrf2-Keap1 defines a physiologically important stress response mechanism.
H. Motohashi (2004)
10.1002/CBF.1149
The role of glutathione in cancer
G. Balendiran (2004)
10.1023/A:1025803600840
Heme oxygenase-1 accelerates tumor angiogenesis of human pancreatic cancer
M. Sunamura (2004)
10.1016/J.DRUP.2004.01.004
ROS stress in cancer cells and therapeutic implications.
H. Pelicano (2004)
10.1158/0008-5472.CAN-05-0237
Phenethyl isothiocyanate and sulforaphane and their N-acetylcysteine conjugates inhibit malignant progression of lung adenomas induced by tobacco carcinogens in A/J mice.
C. Conaway (2005)
10.1128/MCB.25.14.5933-5946.2005
Nrf1 and Nrf2 Regulate Rat Glutamate-Cysteine Ligase Catalytic Subunit Transcription Indirectly via NF-κB and AP-1
Heping Yang (2005)
10.1096/fj.05-3875com
Heme oxygenase‐1 inhibits rat and human breast cancer cell proliferation: mutual cross inhibition with indoleamine 2,3‐dioxygenase
M. Hill (2005)
10.1093/CARCIN/BGL049
Cancer chemoprevention of intestinal polyposis in ApcMin/+ mice by sulforaphane, a natural product derived from cruciferous vegetable.
R. Hu (2006)
10.1038/sj.emboj.7601243
Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling
S. Lo (2006)
10.1074/jbc.M604120200
Arsenic Induces NAD(P)H-quinone Oxidoreductase I by Disrupting the Nrf2·Keap1·Cul3 Complex and Recruiting Nrf2·Maf to the Antioxidant Response Element Enhancer*
X. He (2006)
10.1016/J.CANLET.2005.05.007
Sulforaphane prevents mouse skin tumorigenesis during the stage of promotion.
J. Gills (2006)
10.1080/10408360500523878
Glutathione in Cancer Biology and Therapy
J. Estrela (2006)
10.1016/J.MRREV.2006.02.001
Arsenic in the aetiology of cancer.
S. Tapio (2006)
10.1016/J.CANLET.2005.09.012
Protection against UV-light-induced skin carcinogenesis in SKH-1 high-risk mice by sulforaphane-containing broccoli sprout extracts.
A. Dinkova-Kostova (2006)
10.1158/0008-5472.CAN-05-3462
Inhibition of glutamate cysteine ligase activity sensitizes human breast cancer cells to the toxicity of 2-deoxy-D-glucose.
Kelly K. Andringa (2006)
10.2741/2068
Glutamine, gene expression, and cell function.
R. Curi (2007)
10.1128/MCB.01338-07
Loss of the SdhB, but Not the SdhA, Subunit of Complex II Triggers Reactive Oxygen Species-Dependent Hypoxia-Inducible Factor Activation and Tumorigenesis
R. Guzy (2007)
10.1038/sj.emboj.7601490
Cytoplasmic destruction of p53 by the endoplasmic reticulum‐resident ubiquitin ligase ‘Synoviolin’
S. Yamasaki (2007)
10.1158/0008-5472.CAN-07-3293
Oncogene addiction.
I. Weinstein (2008)
10.1158/1535-7163.MCT-07-2199
Heme oxygenase-1 inhibits breast cancer invasion via suppressing the expression of matrix metalloproteinase-9
C. Lin (2008)
10.1016/j.bbrc.2008.06.004
Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues.
R. Wang (2008)
10.1038/embor.2008.37
Synoviolin promotes IRE1 ubiquitination and degradation in synovial fibroblasts from mice with collagen‐induced arthritis
Beixue Gao (2008)
10.1158/0008-5472.CAN-07-5003
Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth.
T. Ohta (2008)
10.1073/pnas.0806268105
Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy
T. Shibata (2008)
10.1158/1541-7786.MCR-08-0325
Critical Role of Endogenous Heme Oxygenase 1 as a Tuner of the Invasive Potential of Prostate Cancer Cells
G. Gueron (2009)
10.1016/j.cell.2009.02.024
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
Ji Luo (2009)
10.1128/MCB.01639-08
Acetylation of Nrf2 by p300/CBP Augments Promoter-Specific DNA Binding of Nrf2 during the Antioxidant Response
Zheng-Wu Sun (2009)
10.1111/j.1742-4658.2009.07264.x
An E3 ubiquitin ligase, Synoviolin, is involved in the degradation of immature nicastrin, and regulates the production of amyloid β‐protein
Tomoji Maeda (2009)
10.1016/j.taap.2009.06.010
Nrf2 protects against As(III)-induced damage in mouse liver and bladder.
T. Jiang (2009)
10.1158/1535-7163.MCT-10-0108
Expression of ABCG2 (BCRP) Is Regulated by Nrf2 in Cancer Cells That Confers Side Population and Chemoresistance Phenotype
Anju Singh (2010)
10.2131/JTS.35.419
Reduction of arsenic-induced cytotoxicity through Nrf2/HO-1 signaling in HepG2 cells.
Y. Abiko (2010)
10.1016/j.taap.2010.01.011
The rise of antioxidant signaling--the evolution and hormetic actions of Nrf2.
J. Maher (2010)
10.1002/path.2653
Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin
Yoo Ri Kim (2010)
10.1158/0008-5472.CAN-10-0713
High levels of Nrf2 determine chemoresistance in type II endometrial cancer.
T. Jiang (2010)
10.1093/carcin/bgq105
Nrf2-deficiency creates a responsive microenvironment for metastasis to the lung.
Hironori Satoh (2010)
10.1074/jbc.M109.075770
Interaction between Oxidative Stress Sensor Nrf2 and Xenobiotic-activated Aryl Hydrocarbon Receptor in the Regulation of the Human Phase II Detoxifying UDP-glucuronosyltransferase 1A10*
S. Kalthoff (2010)
10.1158/1535-7163.MCT-09-0589
Loss of Kelch-Like ECH-Associated Protein 1 Function in Prostate Cancer Cells Causes Chemoresistance and Radioresistance and Promotes Tumor Growth
Ping Zhang (2010)
10.1158/0008-5472.CAN-10-1666
Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1.
M. J. Seltzer (2010)
10.3109/10715761003667554
Reactive oxygen species in cancer
G. Liou (2010)
10.1073/pnas.1014275108
Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism
Dongmei Ren (2011)
10.1083/jcb.201102095
Signal transduction by reactive oxygen species
T. Finkel (2011)
10.1128/MCB.01204-10
SCF/β-TrCP Promotes Glycogen Synthase Kinase 3-Dependent Degradation of the Nrf2 Transcription Factor in a Keap1-Independent Manner
P. Rada (2011)
10.1038/nchembio.736
Peroxide-dependent sulfenylation of the EGFR catalytic site enhances kinase activity.
C. E. Paulsen (2011)
10.1038/nature10189
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
G. DeNicola (2011)
10.1007/s00204-011-0675-4
Nrf2: control of sensitivity to carcinogens
Stephen L. Slocum (2011)
10.3389/fphar.2012.00030
Direct Antioxidant Properties of Bilirubin and Biliverdin. Is there a Role for Biliverdin Reductase?
T. Jansen (2012)
10.1021/jm301191p
Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors.
K. Shukla (2012)
10.1038/onc.2011.628
Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers
T. Yamadori (2012)
10.1124/dmd.112.045112
Coordinated Regulation of Hepatic Phase I and II Drug-Metabolizing Genes and Transporters using AhR-, CAR-, PXR-, PPARα-, and Nrf2-Null Mice
L. Aleksunes (2012)
10.1128/MCB.00180-12
Structural and Functional Characterization of Nrf2 Degradation by the Glycogen Synthase Kinase 3/β-TrCP Axis
P. Rada (2012)
10.1158/2159-8290.CD-12-0095
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.
E. Cerami (2012)
10.1093/nar/gks827
Nrf2–MafG heterodimers contribute globally to antioxidant and metabolic networks
Yosuke Hirotsu (2012)
10.1182/blood-2012-04-422121
The high Nrf2 expression in human acute myeloid leukemia is driven by NF-κB and underlies its chemo-resistance.
S. Rushworth (2012)
10.1016/j.cmet.2011.12.009
Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells.
A. Le (2012)
10.1016/j.cellsig.2012.01.008
Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling.
P. Ray (2012)
10.1093/jnci/djt201
Hypoxia-inducible factor signaling in pheochromocytoma: turning the rudder in the right direction.
I. Jochmanová (2013)
10.7314/APJCP.2013.14.9.5231
Nrf2 overexpression predicts prognosis and 5-FU resistance in gastric cancer.
X. Hu (2013)
10.1016/j.celrep.2012.12.007
Proteostasis modulators prolong missense VHL protein activity and halt tumor progression.
C. Yang (2013)
10.1126/scisignal.2004088
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
J. Gao (2013)
10.1182/blood-2012-10-460972
Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas.
C. Yang (2013)
10.1111/bjh.12431
Novel compound VHL heterozygosity (VHL T124A/L188V) associated with congenital polycythaemia
F. Lorenzo (2013)
10.1186/2049-3002-2-17
Mitochondrial reactive oxygen species and cancer
Lucas B. Sullivan (2014)
10.1158/1535-7163.MCT-13-0870
Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Matt I. Gross (2014)
10.1101/gad.238246.114
Hrd1 suppresses Nrf2-mediated cellular protection during liver cirrhosis.
Tongde Wu (2014)
10.1002/jcb.24684
ErbB2 Activation Upregulates Glutaminase 1 Expression Which Promotes Breast Cancer Cell Proliferation
Shuo Qie (2014)
Nrf2 induces cisplatin resistance through activation of autophagy in ovarian carcinoma.
L. Bao (2014)
10.1038/bcj.2014.45
The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma
A. Tagde (2014)
10.1016/j.freeradbiomed.2015.06.006
Molecular basis of the Keap1-Nrf2 system.
T. Suzuki (2015)
10.1038/ng.3252
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets
K. Schulze (2015)
10.1038/hgv.2015.53
Somatic mosaicism of EPAS1 mutations in the syndrome of paraganglioma and somatostatinoma associated with polycythemia
C. Yang (2015)
10.1016/j.freeradbiomed.2015.06.014
p62 links autophagy and Nrf2 signaling.
T. Jiang (2015)
10.1182/blood-2015-01-621870
Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.
N. Jacque (2015)
10.1073/pnas.1507228112
MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism
Emelyn H. Shroff (2015)
10.1111/asj.12550
Aflatoxin B1 impairs mitochondrial functions, activates ROS generation, induces apoptosis and involves Nrf2 signal pathway in primary broiler hepatocytes.
Y. Liu (2016)
10.3390/ijms17070997
Brusatol Enhances the Radiosensitivity of A549 Cells by Promoting ROS Production and Enhancing DNA Damage
Xiaohui Sun (2016)
10.1002/pbc.25994
A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High‐Risk Neuroblastoma
J. Villablanca (2016)
10.18632/oncotarget.12944
Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes
Polina R Matre (2016)
10.18632/oncotarget.10129
NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells
C. Rocha (2016)
10.1126/scitranslmed.aad6095
NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis
Hui Wang (2016)
10.1038/ng.3564
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
Joshua D. Campbell (2016)
10.1093/toxsci/kfw065
Generation of a New Model Rat: Nrf2 Knockout Rats Are Sensitive to Aflatoxin B1 Toxicity.
Keiko Taguchi (2016)
10.1038/cddis.2016.404
Dual targeting of glutaminase 1 and thymidylate synthase elicits death synergistically in NSCLC
Jae-Seon Lee (2016)
10.1080/03602532.2016.1197239
Emerging role of NRF2 in chemoresistance by regulating drug-metabolizing enzymes and efflux transporters
Xupeng Bai (2016)
10.18632/oncotarget.12435
NRF2 promotes breast cancer cell proliferation and metastasis by increasing RhoA/ROCK pathway signal transduction
C. Zhang (2016)
10.1016/j.freeradbiomed.2016.09.010
An overview of chemical inhibitors of the Nrf2-ARE signaling pathway and their potential applications in cancer therapy.
Jiayu Zhu (2016)
10.1038/ncb3341
Glutathione biosynthesis is a metabolic vulnerability in PI3K/Akt-driven breast cancer
Evan C. Lien (2016)
10.1038/emm.2017.15
Inhibition of glutathione metabolism attenuates esophageal cancer progression
Liang Peng (2017)
10.18632/oncotarget.16262
Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells
R. Thompson (2017)
10.3389/fonc.2017.00085
The KEAP1–NRF2 System in Cancer
Keiko Taguchi (2017)
10.1016/j.ccell.2018.03.022
NRF2 and the Hallmarks of Cancer.
Montserrat Rojo de la Vega (2018)
10.1016/j.semcdb.2017.05.023
ROS signalling in the biology of cancer.
Jennifer N. Moloney (2018)
10.1016/j.cell.2018.08.038
Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma
Samuel K. McBrayer (2018)
10.1155/2018/2360427
Brusatol Enhances the Chemotherapy Efficacy of Gemcitabine in Pancreatic Cancer via the Nrf2 Signalling Pathway
Yukai Xiang (2018)
10.1093/jnci/djy230
Targeting IDH1-Mutated Malignancies with NRF2 Blockade.
Y. Liu (2019)
10.1158/1535-7163.MCT-19-0103
Blockade of Glutathione Metabolism in IDH1-Mutated Glioma
Xiaoying Tang (2019)
10.1093/nar/gkz348
WashU Epigenome Browser update 2019
Daofeng Li (2019)
10.1016/j.cell.2019.06.003
Nrf2 Activation Promotes Lung Cancer Metastasis by Inhibiting the Degradation of Bach1
Luca Lignitto (2019)
10.3390/cancers11040436
Pheochromocytomas and Paragangliomas: From Genetic Diversity to Targeted Therapies
Ying Pang (2019)
10.1186/s13578-019-0309-8
Brusatol, an NRF2 inhibitor for future cancer therapeutic
Sabrina J. Cai (2019)
10.1080/09553002.2018.1558299
Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice
G. Boysen (2019)
10.1158/1078-0432.CCR-19-2335
Therapeutic Targeting of SDHB-Mutated Pheochromocytoma/Paraganglioma with Pharmacologic Ascorbic Acid
Y. Liu (2020)
10.1073/pnas.1913633117
Triptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione metabolism
Di Yu (2020)
10.3390/cancers12020280
Targeting NRF2-Governed Glutathione Synthesis for SDHB-Mutated Pheochromocytoma and Paraganglioma
Y. Liu (2020)
10.3390/cancers12040787
mTORC2/Rac1 Pathway Predisposes Cancer Aggressiveness in IDH1-Mutated Glioma
Y. Liu (2020)
10.1038/s41416-020-0814-x
IDH mutation in glioma: molecular mechanisms and potential therapeutic targets
Sue Han (2020)



This paper is referenced by
10.1002/smll.202101368
A Ferrocene-Functionalized Covalent Organic Framework for Enhancing Chemodynamic Therapy via Redox Dyshomeostasis.
Le Zhou (2021)
10.1158/1535-7163.MCT-21-0210
A Novel Nrf2 Pathway Inhibitor Sensitizes Keap1-Mutant Lung Cancer Cells to Chemotherapy
Di Zhang (2021)
10.1038/s41419-021-03968-2
The intrinsic role and mechanism of tumor expressed-CD38 on lung adenocarcinoma progression
Long Gao (2021)
10.3390/molecules26051417
Therapeutic Targeting of the NRF2 Signaling Pathway in Cancer
Pelin Telkoparan-Akillilar (2021)
10.1007/s12079-021-00619-1
CSNK2B contributes to colorectal cancer cell proliferation by activating the mTOR signaling
Shijun Yu (2021)
10.1186/s13046-021-02069-4
Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer
Chunfeng Xie (2021)
10.1186/s13046-021-02026-1
Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma
Fengzhi Li (2021)
10.3389/fphar.2021.620921
The Role of Nrf2 in Hearing Loss
Dafei Li (2021)
10.3390/cancers13153769
Reactive Oxygen Species: A Promising Therapeutic Target for SDHx-Mutated Pheochromocytoma and Paraganglioma
Katerina Hadrava Vanova (2021)
10.1016/j.cbi.2021.109464
Thresholds for Carcinogens.
E. Calabrese (2021)
10.3390/antiox10081260
Exogenous Antioxidants Impact on UV-Induced Changes in Membrane Phospholipids and the Effectiveness of the Endocannabinoid System in Human Skin Cells
A. Gęgotek (2021)
10.3390/ijms21197346
Involvement of Mitochondrial Mechanisms in the Cytostatic Effect of Desethylamiodarone in B16F10 Melanoma Cells
Fadi H J Ramadan (2020)
10.1016/j.phrs.2020.105283
THE PHYTOPROTECTIVE AGENT SULFORAPHANE PREVENTS INFLAMMATORY DEGENERATIVE DISEASES AND AGE-RELATED PATHOLOGIES VIA NRF2-MEDIATED HORMESIS.
E. Calabrese (2020)
Semantic Scholar Logo Some data provided by SemanticScholar